Nangibotide
Investigational — sepsis immunomodulator peptide — not approved.
Ref $ —reference only
NangibotideIn clinical trials · Not yet FDA-approvedWhat it's for
Investigational — sepsis immunomodulator peptide — not approved.
What it's for
Nangibotide is an still being studied peptide that inhibits triggering receptors (lock-and-key landing spots on cells) expressed on myeloid cells-1 (TREM-1).
What it does for the body
Studied to gently adjust harmful innate immune amplification in septic shock. Not approved. People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.
What it targets
Blocking TREM-1 signaling aims to reduce immune signaling chemicals amplification without fully ablating host defense. Researchers map these ideas in cells and animals first; human proof has to clear a higher bar.
Research context
Bottom line for readers: Nangibotide is still being studied in people. Watch for peer-reviewed trial readouts and regulator decisions — not just social-media summaries.
Studied for (literature interest)
- Immune research interest (educational tag)
Cautions (educational)
- Educational only — not medical advice.
- DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.
Citations / starters
- FDA search: Nangibotide — FDA.gov search
- ClinicalTrials.gov search: Nangibotide — U.S. clinical trials registry
- Drugs@FDA search: Nangibotide — FDA drug database (if approved)
- PubMed search: Nangibotide — NCBI PubMed
- PubMed Central search: Nangibotide — NCBI PMC
Reference
No ref on file.